Savlon Antiseptic Cream Cetrimide 0.5% w/wChlorhexidine Digluconate 0.1% w/w

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Cetrimide; Chlorhexidine gluconate

제공처:

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

ATC 코드:

D08AJ; D08AJ04

INN (국제 이름):

Cetrimide; Chlorhexidine gluconate

복용량:

0.5/0.1 percent weight/weight

약제 형태:

Cream

처방전 유형:

Product not subject to medical prescription

치료 영역:

Quaternary ammonium compounds; cetrimide

승인 상태:

Marketed

승인 날짜:

1991-06-26

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Savlon Antiseptic Cream
Cetrimide 0.5% w/w
Chlorhexidine Digluconate 0.1% w/w
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredients:
Cetrimide 0.50% w/w
Chlorhexidine digluconate 0.10% w/w
Excipients:
Cetostearyl alcohol 10.00% w/w
Methyl parahydroxybenzoate (E218) 0.01% w/w
Propyl parahydroxybenzoate (E216) 0.01% w/w
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Cream.
Smooth, white, homogenous cream with an antiseptic odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For prevention and management of superficial infections in skin tissue
including wounds and minor burns.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
For cutaneous use.
Apply the cream over the affected area after cleansing.
4.3 CONTRAINDICATIONS
Hypersensitivity to chlorhexidine digluconate, cetrimide or to any of
the excipient listed in section 6.1
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
For external use only.
Avoid contact with the eyes, ears, mouth or other mucosa.
If accidentally splashed into the eye, the open eye should be
irrigated for at least 10 minutes.
If symptoms persist or condition worsens, discontinue use and consult
a physician.
The product is incompatible with anionic substances (e.g. soap).
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_3_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_8_
_C_
_R_
_N_
_ _
_2_
_2_
_0_
_5_
_9_
_8_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
Information concern